The Covid-19 pandemic has, together with the rapid rise of medical technology and boom in M&A over the past couple of years, created something of a perfect storm for investment abuses in the medtech sector.
The pandemic itself has created an acute need for complex products with demanding levels of precision on a scale previously unknown - from antigen tests to monitoring equipment such as pulse oximeters, to contact-tracing apps and even ambitious spatial detection devices. Demand is considerable in both the consumer and B2B markets. If the pandemic pushed many consumers to take a greater interest in their health, the buoyant state of medical technology itself was well positioned to receive them. Wearables such as smartwatches and fitness trackers with increasingly sophisticated health mark...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes